WO2001015664A2 - Procedes de coformulation et leurs produits - Google Patents

Procedes de coformulation et leurs produits Download PDF

Info

Publication number
WO2001015664A2
WO2001015664A2 PCT/GB2000/003328 GB0003328W WO0115664A2 WO 2001015664 A2 WO2001015664 A2 WO 2001015664A2 GB 0003328 W GB0003328 W GB 0003328W WO 0115664 A2 WO0115664 A2 WO 0115664A2
Authority
WO
WIPO (PCT)
Prior art keywords
coformulation
active substance
oligomeric
polymeric material
paracetamol
Prior art date
Application number
PCT/GB2000/003328
Other languages
English (en)
Other versions
WO2001015664A3 (fr
Inventor
Peter York
Simon Anthony Wilkins
Richard Anthony Storey
Stephen Ernest Walker
Ronald Scott Harland
Original Assignee
Bradford Particle Design Limited
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bradford Particle Design Limited, Bristol-Myers Squibb Company filed Critical Bradford Particle Design Limited
Priority to MXPA02001803A priority Critical patent/MXPA02001803A/es
Priority to AU68550/00A priority patent/AU783570B2/en
Priority to EP00956682A priority patent/EP1207856A2/fr
Priority to KR1020027002715A priority patent/KR20020047137A/ko
Priority to JP2001519878A priority patent/JP2003508419A/ja
Priority to CA002382556A priority patent/CA2382556A1/fr
Publication of WO2001015664A2 publication Critical patent/WO2001015664A2/fr
Publication of WO2001015664A3 publication Critical patent/WO2001015664A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/04—Solvent extraction of solutions which are liquid
    • B01D11/0403—Solvent extraction of solutions which are liquid with a supercritical fluid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/04—Solvent extraction of solutions which are liquid
    • B01D11/0403—Solvent extraction of solutions which are liquid with a supercritical fluid
    • B01D11/0407—Solvent extraction of solutions which are liquid with a supercritical fluid the supercritical fluid acting as solvent for the solute
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/04—Solvent extraction of solutions which are liquid
    • B01D11/0403—Solvent extraction of solutions which are liquid with a supercritical fluid
    • B01D11/0411—Solvent extraction of solutions which are liquid with a supercritical fluid the supercritical fluid acting as solvent for the solvent and as anti-solvent for the solute, e.g. formation of particles from solutions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/04—Solvent extraction of solutions which are liquid
    • B01D11/0488—Flow sheets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une coformulation d'une substance active (de préférence active au plan pharmaceutique, comme par exemple un inhibiteur enzymatique COX-2) et d'un excipient oligomère ou polymère, contenant au moins 10 % de substance active dont 80 à 100 % est actif. La phase amorphe est stable, par rapport à la/aux phases cristallines, pendant au moins trois mois après sa préparation, lorsqu'elle est stockée entre 0 et 10 °C. L'invention porte également sur des procédés, impliquant de préférence la formation de particules SEDSTM, pour la préparation de ladite coformulation.
PCT/GB2000/003328 1999-08-31 2000-08-31 Procedes de coformulation et leurs produits WO2001015664A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
MXPA02001803A MXPA02001803A (es) 1999-08-31 2000-08-31 Metodos de coformulacion y sus productos.
AU68550/00A AU783570B2 (en) 1999-08-31 2000-08-31 Coformulation methods and their products
EP00956682A EP1207856A2 (fr) 1999-08-31 2000-08-31 Procedes de coformulation et leurs produits
KR1020027002715A KR20020047137A (ko) 1999-08-31 2000-08-31 공조제 방법 및 그것의 산물
JP2001519878A JP2003508419A (ja) 1999-08-31 2000-08-31 共配合方法およびそれらの製品
CA002382556A CA2382556A1 (fr) 1999-08-31 2000-08-31 Procedes de coformulation et leurs produits

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9920558.5 1999-08-31
GBGB9920558.5A GB9920558D0 (en) 1999-08-31 1999-08-31 Methods for particle formation and their products

Publications (2)

Publication Number Publication Date
WO2001015664A2 true WO2001015664A2 (fr) 2001-03-08
WO2001015664A3 WO2001015664A3 (fr) 2001-09-20

Family

ID=10860085

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/003328 WO2001015664A2 (fr) 1999-08-31 2000-08-31 Procedes de coformulation et leurs produits

Country Status (8)

Country Link
EP (1) EP1207856A2 (fr)
JP (1) JP2003508419A (fr)
KR (1) KR20020047137A (fr)
AU (1) AU783570B2 (fr)
CA (1) CA2382556A1 (fr)
GB (2) GB9920558D0 (fr)
MX (1) MXPA02001803A (fr)
WO (1) WO2001015664A2 (fr)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2371501A (en) * 2000-11-09 2002-07-31 Bradford Particle Design Ltd Particle formation methods and their products
FR2825292A1 (fr) * 2001-05-30 2002-12-06 Csir Procede d'enrobage d'une substance active dans un complexe interpolymere
EP1263412A1 (fr) 2000-03-04 2002-12-11 Eco2 SA Produits pharmaceutiques microfins
WO2003035673A1 (fr) 2001-10-22 2003-05-01 Dompe S.P.A. Traitement de fluides supercritiques : preparation de microparticules de proteines et leur stabilisation
US6964978B2 (en) 1999-12-08 2005-11-15 Pharmacia Corporation Solid-state form of celecoxib having enhanced bioavailability
US7108867B2 (en) 2001-01-26 2006-09-19 Astrazeneca Ab Process for preparing particles
WO2007018887A2 (fr) * 2005-07-25 2007-02-15 Hewlett-Packard Development Company, L.P. Application d'un agent bioactif sur un substrat
WO2007018953A1 (fr) * 2005-07-25 2007-02-15 Hewlett-Packard Development Company, L.P. Preparation de nanoparticules
WO2007018954A2 (fr) * 2005-07-25 2007-02-15 Hewlett-Packard Development Company, L.P. Application d'un agent bioactif dans une composition de solvant en vue de l'obtention d'une morphologie particulaire cible
US7354601B2 (en) 2003-05-08 2008-04-08 Walker Stephen E Particulate materials
WO2008096144A1 (fr) * 2007-02-08 2008-08-14 Thar Pharmaceuticals Inc. Procédé de création de substances cristallines
US7507823B2 (en) 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
EP1330266B2 (fr) † 2000-10-19 2009-08-26 Separex Procede de fabrication de tres fines particules constituees d'un principe insere dans une molecule hote
US7744923B2 (en) 2006-10-11 2010-06-29 Crititech, Inc. Method for precipitation of small medicament particles into use containers
EP2612703A2 (fr) 2002-04-17 2013-07-10 Nektar Therapeutics Matériau à particules
US8585942B2 (en) 2007-12-07 2013-11-19 Xspray Microparticles Ab Process and arrangement for producing particles utilizing subcritical fluids
US9023393B2 (en) 2003-08-04 2015-05-05 Bend Research, Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
US9226900B2 (en) 2008-07-11 2016-01-05 Critical Pharmaceuticals Limited Process for preparing microparticles
US9468604B2 (en) 2001-06-22 2016-10-18 Bend Research, Inc. Pharmaceutical compositions of dispersions of drug and neutral polymers
US9486410B2 (en) 2002-02-01 2016-11-08 Bend Research, Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
US9700529B2 (en) 2002-05-03 2017-07-11 Nektar Therapeutics Particulate materials
US9808030B2 (en) 2011-02-11 2017-11-07 Grain Processing Corporation Salt composition
US9833451B2 (en) 2007-02-11 2017-12-05 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037303A1 (fr) 2001-11-01 2003-05-08 Nektar Therapeutics Procedes de sechage par atomisation et compositions associees
MX371297B (es) * 2012-01-13 2020-01-24 Xspray Microparticles Ab Una composición farmacéutica que comprende nanopartículas híbridas amorfas estables, de al menos un inhibidor de proteína quinasa y al menos un componente estabilizador polimérico y formador de matriz.
EP3181128B1 (fr) * 2012-01-13 2023-03-08 XSpray Pharma AB (publ) Composition pharmaceutique du nilotinib

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4404183A (en) * 1979-07-05 1983-09-13 Yamanouchi Pharmaceutical Co., Ltd. Sustained release pharmaceutical composition of solid medical material
WO1992011000A1 (fr) * 1990-12-22 1992-07-09 Schwarz Pharma Ag Procede pour la fabrication de microparticules constituees de polymeres hydrolytiquement degradables et contenant des principes actifs
EP0582169A2 (fr) * 1992-08-05 1994-02-09 Bayer S.p.A. Préparations pharmaceutiques pour l'administration orale des dihydropyridines sous forme de boisson
WO1995001221A1 (fr) * 1993-07-01 1995-01-12 University Of Bradford Procede et appareillage permettant la formation de particules
WO1996031202A1 (fr) * 1995-04-03 1996-10-10 Elan Corporation, Plc Microspheres et nanospheres biodegradables a liberation lente renfermant de la cyclosporine
WO1997031691A1 (fr) * 1996-03-01 1997-09-04 The University Of Kansas Procedes et appareil pour la precipitation et l'enrobage de particules au moyen d'antisolvants quasi-critiques et supercritiques
WO1997044028A1 (fr) * 1996-05-17 1997-11-27 Merck & Co., Inc. Compositions pour traitement journalier monodose de maladies a mediateur cyclooxygenase-2
WO1998013136A1 (fr) * 1996-09-25 1998-04-02 Mainelab Procede de preparation de microcapsules de matieres actives enrobees par un polymere et nouvelles microcapsules notamment obtenues selon le procede
EP0852140A1 (fr) * 1995-08-11 1998-07-08 Nissan Chemical Industries, Limited Procedes permettant de rendre amorphes des medicaments peu solubles
WO1999025322A2 (fr) * 1997-11-19 1999-05-27 Eurand International S.P.A. Compositions pharmaceutiques ayant la forme de poudres de polymeres reticules charges de medicaments et procede de preparation correspondant au moyen de fluides supercritiques
WO2001003821A1 (fr) * 1999-07-07 2001-01-18 Bradford Particle Design Limited Procede de formation de particules

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0462066A1 (fr) * 1990-06-15 1991-12-18 Warner-Lambert Company Gemfibrozil amorphe
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
SI9500173B (sl) * 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
US5980942A (en) * 1997-01-23 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release matrix tablet formulations of carbamazepine
DE19821951A1 (de) * 1998-05-15 1999-11-18 Basf Ag Cyclosporin-Zubereitungen
US6465011B2 (en) * 1999-05-29 2002-10-15 Abbott Laboratories Formulations comprising lipid-regulating agents

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4404183A (en) * 1979-07-05 1983-09-13 Yamanouchi Pharmaceutical Co., Ltd. Sustained release pharmaceutical composition of solid medical material
WO1992011000A1 (fr) * 1990-12-22 1992-07-09 Schwarz Pharma Ag Procede pour la fabrication de microparticules constituees de polymeres hydrolytiquement degradables et contenant des principes actifs
EP0582169A2 (fr) * 1992-08-05 1994-02-09 Bayer S.p.A. Préparations pharmaceutiques pour l'administration orale des dihydropyridines sous forme de boisson
WO1995001221A1 (fr) * 1993-07-01 1995-01-12 University Of Bradford Procede et appareillage permettant la formation de particules
WO1996031202A1 (fr) * 1995-04-03 1996-10-10 Elan Corporation, Plc Microspheres et nanospheres biodegradables a liberation lente renfermant de la cyclosporine
EP0852140A1 (fr) * 1995-08-11 1998-07-08 Nissan Chemical Industries, Limited Procedes permettant de rendre amorphes des medicaments peu solubles
WO1997031691A1 (fr) * 1996-03-01 1997-09-04 The University Of Kansas Procedes et appareil pour la precipitation et l'enrobage de particules au moyen d'antisolvants quasi-critiques et supercritiques
WO1997044028A1 (fr) * 1996-05-17 1997-11-27 Merck & Co., Inc. Compositions pour traitement journalier monodose de maladies a mediateur cyclooxygenase-2
WO1998013136A1 (fr) * 1996-09-25 1998-04-02 Mainelab Procede de preparation de microcapsules de matieres actives enrobees par un polymere et nouvelles microcapsules notamment obtenues selon le procede
WO1999025322A2 (fr) * 1997-11-19 1999-05-27 Eurand International S.P.A. Compositions pharmaceutiques ayant la forme de poudres de polymeres reticules charges de medicaments et procede de preparation correspondant au moyen de fluides supercritiques
WO2001003821A1 (fr) * 1999-07-07 2001-01-18 Bradford Particle Design Limited Procede de formation de particules

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DEBENEDETTI P G ET AL: "APPLICATION OF SUPERCRITICAL FLUIDS FOR THE PRODUCTION OF SUSTAINED DELIVERY DEVICES" JOURNAL OF CONTROLLED RELEASE,NL,ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, vol. 24, no. 1 / 03, 1 May 1993 (1993-05-01), pages 27-44, XP000303918 ISSN: 0168-3659 *
SHEKUNOV B. ET AL: "Control of Particle Morphology using solution enhanced dispersion by supercritical fluids (SEDS)" PHARM. RES., vol. 14, 1997, pages 195-196, XP000905093 *
TAYLOR L. ET AL: "Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions" PHARM. RES., vol. 14, 1997, pages 1691-1698, XP000905065 *
WILKINS S. ET AL: "The formation of indomethacin:polymer co-precipitates by the solution enhanced dispersion by supercritical fluids (SEDS) process" J. OF PHARMACY AND PHARMACOLOGY, vol. 51, September 1999 (1999-09), page 291 XP000905174 *

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6964978B2 (en) 1999-12-08 2005-11-15 Pharmacia Corporation Solid-state form of celecoxib having enhanced bioavailability
EP1263412A1 (fr) 2000-03-04 2002-12-11 Eco2 SA Produits pharmaceutiques microfins
EP1330266B2 (fr) † 2000-10-19 2009-08-26 Separex Procede de fabrication de tres fines particules constituees d'un principe insere dans une molecule hote
GB2371501B (en) * 2000-11-09 2003-05-14 Bradford Particle Design Ltd Particle formation methods and their products
GB2371501A (en) * 2000-11-09 2002-07-31 Bradford Particle Design Ltd Particle formation methods and their products
US10798955B2 (en) 2000-11-09 2020-10-13 Nektar Therapeutics Compositions of particulate coformulation
US7115280B2 (en) 2000-11-09 2006-10-03 Nektar Therapeutics Uk, Ltd. Particle formation methods and their products
US7108867B2 (en) 2001-01-26 2006-09-19 Astrazeneca Ab Process for preparing particles
US7829123B2 (en) 2001-01-26 2010-11-09 Astrazeneca Ab Process
GB2392619B (en) * 2001-05-30 2004-10-20 Csir Method of encapsulating an active substance
FR2825292A1 (fr) * 2001-05-30 2002-12-06 Csir Procede d'enrobage d'une substance active dans un complexe interpolymere
GB2392619A (en) * 2001-05-30 2004-03-10 Csir Method of encapsulating an active substance
WO2003013478A3 (fr) * 2001-05-30 2003-05-30 Csir Procede d'encapsulation d'une substance active
US7641917B2 (en) 2001-05-30 2010-01-05 Csir Method of encapsulating an active substance
US7767249B2 (en) * 2001-06-07 2010-08-03 Hewlett-Packard Development Company, L.P. Preparation of nanoparticles
US9468604B2 (en) 2001-06-22 2016-10-18 Bend Research, Inc. Pharmaceutical compositions of dispersions of drug and neutral polymers
WO2003035673A1 (fr) 2001-10-22 2003-05-01 Dompe S.P.A. Traitement de fluides supercritiques : preparation de microparticules de proteines et leur stabilisation
US7250152B2 (en) 2001-10-22 2007-07-31 Dompé Pha.R.Ma S.P.A. Supercritical fluids processing: preparation of protein microparticles and their stablilisation
US9486410B2 (en) 2002-02-01 2016-11-08 Bend Research, Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
US10357455B2 (en) 2002-02-01 2019-07-23 Bend Research, Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
US10251881B2 (en) 2002-04-17 2019-04-09 Nektar Therapeutics Particulate materials
US9616060B2 (en) 2002-04-17 2017-04-11 Nektar Therapeutics Particulate materials
EP2612703A2 (fr) 2002-04-17 2013-07-10 Nektar Therapeutics Matériau à particules
US10188614B2 (en) 2002-05-03 2019-01-29 Nektar Therapeutics Particulate materials
US9700529B2 (en) 2002-05-03 2017-07-11 Nektar Therapeutics Particulate materials
US10945972B2 (en) 2002-05-03 2021-03-16 Nektar Therapeutics Particulate materials
US7354601B2 (en) 2003-05-08 2008-04-08 Walker Stephen E Particulate materials
US9023393B2 (en) 2003-08-04 2015-05-05 Bend Research, Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
USRE47033E1 (en) 2003-08-04 2018-09-11 Bend Research, Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
US7507823B2 (en) 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
WO2007018887A3 (fr) * 2005-07-25 2007-06-21 Hewlett Packard Development Co Application d'un agent bioactif sur un substrat
WO2007018887A2 (fr) * 2005-07-25 2007-02-15 Hewlett-Packard Development Company, L.P. Application d'un agent bioactif sur un substrat
WO2007018954A2 (fr) * 2005-07-25 2007-02-15 Hewlett-Packard Development Company, L.P. Application d'un agent bioactif dans une composition de solvant en vue de l'obtention d'une morphologie particulaire cible
WO2007018953A1 (fr) * 2005-07-25 2007-02-15 Hewlett-Packard Development Company, L.P. Preparation de nanoparticules
WO2007018954A3 (fr) * 2005-07-25 2007-06-21 Hewlett Packard Development Co Application d'un agent bioactif dans une composition de solvant en vue de l'obtention d'une morphologie particulaire cible
US7744923B2 (en) 2006-10-11 2010-06-29 Crititech, Inc. Method for precipitation of small medicament particles into use containers
US8241371B2 (en) 2007-02-08 2012-08-14 Thar Pharmaceuticals, Inc. Method of creating crystalline substances
EP2117666A1 (fr) 2007-02-08 2009-11-18 Thar Pharmaceuticals Inc. Procédé de création de substances cristallines
WO2008096144A1 (fr) * 2007-02-08 2008-08-14 Thar Pharmaceuticals Inc. Procédé de création de substances cristallines
US9833451B2 (en) 2007-02-11 2017-12-05 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US10172853B2 (en) 2007-02-11 2019-01-08 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US8585943B2 (en) 2007-12-07 2013-11-19 Xspray Microparticles Ab Method and arrangement for the production of particles
US8585942B2 (en) 2007-12-07 2013-11-19 Xspray Microparticles Ab Process and arrangement for producing particles utilizing subcritical fluids
US9226900B2 (en) 2008-07-11 2016-01-05 Critical Pharmaceuticals Limited Process for preparing microparticles
US9808030B2 (en) 2011-02-11 2017-11-07 Grain Processing Corporation Salt composition

Also Published As

Publication number Publication date
GB0021227D0 (en) 2000-10-18
KR20020047137A (ko) 2002-06-21
JP2003508419A (ja) 2003-03-04
MXPA02001803A (es) 2004-02-26
AU6855000A (en) 2001-03-26
WO2001015664A3 (fr) 2001-09-20
GB9920558D0 (en) 1999-11-03
GB2355194B (en) 2003-01-08
AU783570B2 (en) 2005-11-10
EP1207856A2 (fr) 2002-05-29
CA2382556A1 (fr) 2001-03-08
GB2355194A (en) 2001-04-18

Similar Documents

Publication Publication Date Title
EP1207856A2 (fr) Procedes de coformulation et leurs produits
Majerik et al. Bioavailability enhancement of an active substance by supercritical antisolvent precipitation
Vimalson Techniques to enhance solubility of hydrophobic drugs: an overview
Cid et al. Solid dispersion technology as a strategy to improve the bioavailability of poorly soluble drugs
Won et al. Improved physicochemical characteristics of felodipine solid dispersion particles by supercritical anti-solvent precipitation process
York Strategies for particle design using supercritical fluid technologies
Jatwani et al. An overview on solubility enhancement techniques for poorly soluble drugs and solid dispersion as an eminent strategic approach
Hu et al. Continuous and scalable process for water-redispersible nanoformulation of poorly aqueous soluble APIs by antisolvent precipitation and spray-drying
Vasconcelos et al. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs
Kalpana et al. Solid Dispersion: Approaches, Technology involved, Unmet need & Challenges.
WO1997004749A1 (fr) Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
Lee et al. A novel surface-attached carvedilol solid dispersion with enhanced solubility and dissolution
Li et al. Process parameters and morphology in puerarin, phospholipids and their complex microparticles generation by supercritical antisolvent precipitation
WO2010102245A1 (fr) Dispersion solide comprenant du resvératrol
Che et al. Drug nanocrystals: a state of the art formulation strategy for preparing the poorly water-soluble drugs.
Kamble et al. Norfloxacin mixed solvency based solid dispersions: An in-vitro and in-vivo investigation
Yao et al. Improved oral bioavailability of core–shell structured beads by redispersion of the shell-forming nanoparticles: Preparation, characterization and in vivo studies
Shi et al. The influence of cellulosic polymer’s variables on dissolution/solubility of amorphous felodipine and crystallization inhibition from a supersaturated state
Mohammady et al. Design of ultra-fine carvedilol nanococrystals: development of a safe and stable injectable formulation
Patel et al. Optimization of amorphous solid dispersion techniques to enhance solubility of febuxostat
Roy et al. Theophylline formulation by supercritical antisolvents
Godase et al. A concise review on methods of solubility enhancement
GB2381453A (en) Active/polymer coformulations
Umar et al. Solid Dispersion of Tenoxicam–HPMC by Freeze-Drying: Solid State Properties, Dissolution Study, and Analgesic Activity in Mice
EP2540281A1 (fr) Systèmes à auto-microémulsion solide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/207/KOL

Country of ref document: IN

Ref document number: 68550/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/001803

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2001 519878

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2382556

Country of ref document: CA

Ref document number: 1020027002715

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2000956682

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000956682

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020027002715

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 68550/00

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 2000956682

Country of ref document: EP